Takeda announced that the European Commission, or EC, approved Hyqvia as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy, or CIDP, after stabilization with intravenous immunoglobulin therapy, or IVIG. Takeda previously announced an opinion from the Committee for Medicinal Products for Human Use, or CHMP, on December 15, 2023 and approval as a maintenance therapy for adults with CIDP by the FDA on January 16.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TAK:
- Guggenheim ups CymaBay price target to $28, sees M&A potential
- Halozyme: Takeda receives FDA approval of HYQVIA co-formulated with ENHANZE
- FDA approves Takeda’s HYQVIA to treat CIDP as maintenance therapy
- Takeda announces China NMPA Approval of LIVTENCITY in CMV
- Takeda announces CHMP opinion recommending approval of Hyqvia
